Clinical Edge Journal Scan

Higher disability at early stages raises risk for progression to difficult-to-treat RA


 

Key clinical point: Younger patients and patients with higher disability scores at early stages were more likely to develop difficult-to-treat rheumatoid arthritis (RA). Thus focusing on severe disability during initial stages may alter disease course.

Major finding: Elevated initial disability score (odds ratio [OR] 1.89; P = .01) and a younger age at baseline (OR 0.95; P = .01) were associated with an increased risk for difficult-to-treat RA, whereas initial disease activity failed to show any influence.

Study details: The data come from a longitudinal, prospective cohort study including 631 patients with newly diagnosed RA, of which 35 patients developed difficult-to-treat RA.

Disclosures: This study was supported by the Instituto de Salud Carlos III, Spain, and other sources. The authors did not declare any conflicts of interest.

Source: Leon L et al. Difficult-to-treat rheumatoid arthritis (D2T RA): Clinical issues at early stages of disease. RMD Open . 2023;9:e002842 (Mar 8). Doi: 10.1136/rmdopen-2022-002842

Recommended Reading

Expert offers caveats to perioperative antirheumatic drug guideline
MDedge Rheumatology
What’s holding back physicians from prescribing biosimilars? Four specialties weigh in
MDedge Rheumatology
Bacteremia, antibodies link periodontal disease to RA development and activity
MDedge Rheumatology
FDA approves first biologic treatment for polymyalgia rheumatica
MDedge Rheumatology
Commentary: ILD and other issues in RA treatment, March 2023
MDedge Rheumatology
Call it preclinical or subclinical, ILD in RA needs to be tracked
MDedge Rheumatology
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
MDedge Rheumatology
New JAK inhibitor study data confirm benefit in alopecia areata
MDedge Rheumatology
Tofacitinib may have possible protective effect against ILD in RA
MDedge Rheumatology
Administering concomitant methotrexate at a half vs usual dose while initiating TNFi is feasible
MDedge Rheumatology